Cracking the Genomic Code of CDK4/6 Inhibitor Resistance.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38319645.
- Also identified by DOI 10.1158/1078-0432.CCR-23-3413.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The therapeutic approach to metastatic hormone receptor-positive, human epidermal growth factor-2-negative metastatic breast cancer (HR+/HER2- MBC) has evolved rapidly over recent years. The cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have become first-line targeted agents of choice, in combination with an antiestrogen. Simultaneously, the clinical landscape of therapeutic options has been rapidly shifting, with novel antiestrogens, signal transduction inhibitors, and next-generation CDK inhibitors in various stages of development. Given these dynamic changes, understanding the genomic and molecular landscape of resistance to currently available antiestrogen therapy and CDK4/6 inhibitors represents a major focus of translational breast cancer research globally. See related article by Goetz et al., p. 2233.
Medical subject headings
- Breast Neoplasms
- Cyclin-Dependent Kinase 4
- Cyclin-Dependent Kinase 6
- Drug Resistance, Neoplasm
- Protein Kinase Inhibitors